We applied the developed ESR1-NAPA assay to analyze 13 primary tumours from ER-positive breast cancer patients, and from 13 non-cancerous breast tissues (mammoplasties), which were used as the wtDNA control. The gene discussed is ESR1; the disease is neoplasm.